Argentina's Sinergium turns to cell-based technology for new vaccine production

Sinergium Biotech will build a $50 million vaccine plant in Buenos Aires province that will utilize recombinant technology for work on a Zika virus vaccine, as well as the flu vaccines it already produces.

Argentina's Sinergium Biotech, which is in a consortium to develop a Zika virus vaccine, intends to build a new plant that will use cell biology that can be utilized for a Zika vaccine or for the flu vaccine production it already does.

The company will invest about $50 million to build a plant in Buenos Aires province for primary antigen production, reports Argentinian news service EFE.

The new plant will utilize recombinant technology, which produces product much faster than the egg-based process traditionally used, so the company can respond more quickly to pandemic situations, Fernando Lobos, Sinergium's business development director, has said.

Webinar This Week

OTC Innovation to Avoid Stagnation: Survey Insights, Expert Advice, and Latest Technologies to Boost Your Product’s Performance

Join us for a complimentary webinar on November 13 at 11am ET / 8am PT. Listen to industry experts as they analyze the critical role of innovation in OTC products, and strategies for achieving it.

Last year, Sinergium joined Meriden, Connecticut-based Protein Sciences and the Mundo Sano foundation to jointly develop a Zika virus vaccine based on production of recombinant variations of the virus' E protein.

Sinergium will pay an undisclosed fee to fund the development and manufacturing of the Zika vaccine candidate under development at Protein Sciences, maker of the Flublok influenza vaccine. In return, Sinergium will receive manufacturing and commercial rights to the vaccine in Argentina and some other countries.

Sinergium currently produces flu vaccines, a pneumococcal conjugate vaccine and a tetravalent vaccine.

Because recombinant technology reduces the production time for vaccines from months to weeks, Novartis employed it in a $1 billion U.S. influenza vaccine plant it opened in 2011. The facility was partly funded under a federal grant that would allow the U.S. to divert some production for its own use in case of a pandemic. Novartis sold the plant to Australia-based CSL for $275 million in 2015 when the Swiss drugmaker decided to exit the vaccine business.

Suggested Articles

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Drugmakers have voluntarily recalled their generic Zantac from the U.S. market after the FDA raised concerns, but it has not been without a cost.

Just weeks after selling the sterile manufacturing assets of its Kyowa operation in Japan, it has unloaded the rest of its Kyowa drugmaking operation.